ES2319997T3 - Lipolisis local selectiva medicamentosa. - Google Patents

Lipolisis local selectiva medicamentosa. Download PDF

Info

Publication number
ES2319997T3
ES2319997T3 ES04765912T ES04765912T ES2319997T3 ES 2319997 T3 ES2319997 T3 ES 2319997T3 ES 04765912 T ES04765912 T ES 04765912T ES 04765912 T ES04765912 T ES 04765912T ES 2319997 T3 ES2319997 T3 ES 2319997T3
Authority
ES
Spain
Prior art keywords
acid
phospholipid
weight
use according
bile acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04765912T
Other languages
English (en)
Spanish (es)
Inventor
Peter Boderke
Rainer Pooth
Juergen Sandow
Matthias Gossel
Karl-Heinz Nietsch
Gerhard Sattler
Gerhard Vogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2319997(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Application granted granted Critical
Publication of ES2319997T3 publication Critical patent/ES2319997T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES04765912T 2003-10-24 2004-10-09 Lipolisis local selectiva medicamentosa. Expired - Lifetime ES2319997T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349979 2003-10-24
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse

Publications (1)

Publication Number Publication Date
ES2319997T3 true ES2319997T3 (es) 2009-05-18

Family

ID=34529797

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04765912T Expired - Lifetime ES2319997T3 (es) 2003-10-24 2004-10-09 Lipolisis local selectiva medicamentosa.

Country Status (13)

Country Link
EP (1) EP1684722B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509085A (cg-RX-API-DMAC7.html)
KR (1) KR20060117914A (cg-RX-API-DMAC7.html)
CN (1) CN100482211C (cg-RX-API-DMAC7.html)
AT (1) ATE418965T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285264A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415756A (cg-RX-API-DMAC7.html)
CA (1) CA2543187A1 (cg-RX-API-DMAC7.html)
DE (2) DE10349979B4 (cg-RX-API-DMAC7.html)
ES (1) ES2319997T3 (cg-RX-API-DMAC7.html)
IL (1) IL174525A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004081A (cg-RX-API-DMAC7.html)
WO (1) WO2005041919A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
CN102481305B (zh) 2009-08-25 2015-08-19 美德阿利克斯株式会社 磷脂酰胆碱的经皮组合物及其制备方法
DE102010028365A1 (de) * 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
BR112014029188B1 (pt) * 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
BR112016030341A8 (pt) * 2014-06-27 2021-07-20 Medytox Inc formulação para a remoção não cirúrgica de um depósito de gordura localizada em um indivíduo, método para a remoção não cirúrgica de depósitos de gordura localizada em um indivíduo que tem acúmulo de gordura localizada, e kit
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US12616651B2 (en) 2014-11-21 2026-05-05 Lipodissolve Therapeutics Inc. Topical lipolysis composition and methods
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3479827B1 (en) 2017-04-21 2023-05-10 AMI Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019150594A1 (ja) 2018-01-31 2019-08-08 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
WO2019203543A1 (ko) * 2018-04-18 2019-10-24 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
KR102939043B1 (ko) 2020-06-01 2026-03-16 코스메드 파마소티컬 씨오 쩜 엘티디 미용용 마이크로니들 어레이
CN116889548B (zh) * 2022-03-31 2026-07-21 四川汇宇制药股份有限公司 一种脂质体递药系统及其制备方法和用途
KR20260079596A (ko) 2023-09-27 2026-06-02 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 리포좀 약물 전달 시스템 및 이의 제조 방법, 리포좀 제제, 용도, 이를 포함한 체지방 감소 약물 또는 의료 미용 제품

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592C2 (de) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
DE4122744C2 (de) * 1990-08-06 1994-02-03 Nattermann A & Cie Wäßriges Liposomensystem und Verfahren zu seiner Herstellung
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
DE4308121A1 (de) 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite

Also Published As

Publication number Publication date
CN100482211C (zh) 2009-04-29
KR20060117914A (ko) 2006-11-17
HK1096857A1 (zh) 2007-06-15
CN1870977A (zh) 2006-11-29
ATE418965T1 (de) 2009-01-15
WO2005041919A3 (de) 2005-06-23
DE502004008793D1 (cg-RX-API-DMAC7.html) 2009-02-12
EP1684722B1 (de) 2008-12-31
JP2007509085A (ja) 2007-04-12
EP1684722A2 (de) 2006-08-02
DE10349979B4 (de) 2006-05-18
BRPI0415756A (pt) 2006-12-19
WO2005041919A2 (de) 2005-05-12
CA2543187A1 (en) 2005-05-12
IL174525A0 (en) 2006-08-01
MXPA06004081A (es) 2006-06-27
DE10349979A1 (de) 2005-06-16
AU2004285264A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
US20120329765A1 (en) Medicinal targeted local lipolysis
ES2372499T3 (es) Uso de un detergente para la eliminación no quirúrgica de grasa.
JP5191988B2 (ja) エステル化レシチンを用いたナノリポソーム及びその製造方法、及びこれを含む皮膚疾患の予防又は治療用組成物
WO2020257538A1 (en) Transdermal penetrant formulations containing cannabidiol
US20100004216A1 (en) Medicinal lipolysis of accumulation of fat
CN100482211C (zh) 药物靶向的局部脂解
US20080220021A1 (en) Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
MXPA06006645A (es) Lipolisis medica de acumulos de grasa.
CN108743952A (zh) 局部麻醉药的磷脂-混溶剂-油缓释递药系统组方与制备方法
WO2013168172A1 (en) Depot formulations of a local anesthetic and methods for preparation thereof
CN108366975A (zh) 使用脱氧胆酸和其盐对堆积的脂肪的治疗
RU2530629C2 (ru) Вызываемая медикаментозными средствами липоатрофия для косметических целей
PT1853303E (pt) Composições estabilizadas para administração tópica, e métodos para a sua preparação
JP7034497B2 (ja) 痛み、浮腫及び副作用のない局所脂肪減少用注射剤組成物及びその製造方法
EP1699432A2 (en) Injectable phosphatidylcholine preparations
EP2646012A2 (en) Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
EP4518848A1 (en) Intranasal baclofen
AARON et al. Vibra-Puncture Technique in the Treatment of Localized Neurodermatitis: A Preliminary Study on the Effect of Hydrocortisone Acetate Injected by the Multiple Vibra-Puncture Method into Areas of Lichen Simplex Chronicus
JP7298885B2 (ja) 皮膚外用液剤、脂肪減少剤及び痩身剤
EP4582078A1 (en) Composition for localized fat reduction without pain, edema and side effects and method of administration thereof
SU1297862A1 (ru) Средства дл лечени пигментной дегенерации сетчатки
HK1096857B (en) Medicamentously targeted local lipolysis
BR112019008065B1 (pt) Composição para reduzir gordura, preparação para remover deposição de gordura localizada, kits, métodos para preparar uma composição e uso de fosfatidilcolina